SB 242235|193746-75-7|-陌孚医药/Medlife

您当前的位置：

SB 242235

目录号: PL08728 纯度: ≥99%

CAS No. :193746-75-7

商品编号	规格	价格	会员价
PL08728-2mg	2mg	¥2410.00	请登录
PL08728-5mg	5mg	¥3857.00	请登录
PL08728-10mg	10mg	¥6188.00	请登录
PL08728-50mg	50mg	¥19287.00	请登录
PL08728-100mg	100mg	¥31390.00	请登录
PL08728-200mg	200mg	询价	询价
PL08728-500mg	500mg	询价	询价
PL08728-10mM*1mLinDMSO	10mM*1mLinDMSO	¥2999.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	SB 242235
中文别名	4-[4-(4-氟苯基)-1-(4-哌啶基)-1H-咪唑-5-基]-2-甲氧基嘧啶;SB 242235
英文名称	SB 242235
英文别名	4-(4-(4-Fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl)-2-methoxypyrimidine;4-[5-(4-fluorophenyl)-3-piperidin-4-ylimidazol-4-yl]-2-methoxypyrimidine;SB 242235;SB-242235;4-[4-(4-Fluorophenyl)-1-(4-piperidinyl)-1H-imidazol-5-yl]-2-methoxypyrimidine;SB242235;4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]-2-methoxypyrimidine;Kinome_3169;BDBM15458;SYN1076;HMS3244I17;HMS3244I18;HMS3244J17;BCP05992;3254AH;AB0098302
Cas No.	193746-75-7
分子式	C₁₉H₂₀FN₅O
分子量	353.39
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情	SB-242235　是一种有效、选择性的　p38 MAP 激酶抑制剂，在人的软骨细胞中　IC₅₀　值为 1.0 μM。
生物活性	SB-242235 is a potent and selective p38 MAP kinase inhibitor, with an IC 50 of 1.0　μM in primary human chondrocytes.
性状	Solid
IC50 & Target[1][2]	IC50: 1.0　μM (p38 MAPK, primary human chondrocytes)
体外研究(In Vitro)	SB 242235 (0-10　μM) dose-dependently inhibits the activation of MAPKAP K2 with an IC50 of 1.0 μM in human chondrocytes stimulated with IL-1β. SB 242235 inhibits intracellular p38 activity, MAPKAP K2 was then isolated from these cells and assayed using HSP27 as a substrate. has not independently confirmed the accuracy of these methods. They are for reference only.Western Blot Analysis
体内研究(In Vivo)	SB242235 (100 mg/kg; p.o.) abolishes MAP-KAPK-2 activity and HSP27 phosphorylation. SB242235 inhibits expression of the pro-inflammatory cytokines interleukin (IL)-6 and KC (murine IL-8) and COX-2. SB-242235 is demonstrated non-linear elimination kinetics that manifested as a decrease in clearance with increasing dose and apparent oral bioavailability > 100% at high oral doses in rat and monkey. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Powder -20°C 3 years；4°C 2 years
参考文献	[1]. Badger, A.M., et al., Differential effects of SB 242235, a selective p38 mitogen-activated protein kinase inhibitor, on IL-1 treated bovine and human cartilage/chondrocyte cultures. Osteoarthritis Cartilage, 2000. 8(6): p. 434-43. [2]. Kim AL , et al. Role of p38 MAPK in UVB-induced inflammatory responses in the skin of SKH-1 hairless mice. J Invest Dermatol. 2005 Jun;124(6):1318-25.

溶解度数据	In Vitro: DMSO : ≥ 48 mg/mL (135.83 mM)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation